Close menu




January 13th, 2020 | 11:33 CET

Agrios Global Holdings LTD - still on track

  • Cannabis
Photo credits: pixabay.com

Agrios Global Holdings is an agricultural technology company with a focus on the latest innovations in indoor growing and data analytics. The company's technology can be used for all types of indoor cultivation. The company rents and manages real estate and equipment for environmentally sustainable indoor agriculture. The company offers leasing and cultivation services in the field of data-controlled aeroponic cultivation systems for cannabis producers. Furthermore, the company provides consulting services to support the cannabis sector.

time to read: 1 minutes | Author: Mario Hose
ISIN: CA00856K1003

Table of contents:


    Update to the cannabis market

    Agrios Global Holdings (Agrios) is still a young company with high growth potential, according to the experts at GBC Research. The company currently owns a state-of-the-art production facility in Washington State, which is leased to a licensed cannabis producer and processor. Agrios also leases data-driven aeroponics cultivation systems and cultivation services to cannabis producers. The company's technology can also be used for any type of indoor cultivation.

    The US Indoor Aeroponics market is expected to reach USD 40 billion annually by 2022. In addition, the US cannabis market is estimated to reach USD 75 billion annually by 2030. The market in the state of Washington was still around USD 1.37 billion in 2017 and is expected to grow to USD 2.28 billion by 2020.

    Sales increase compared to the previous year

    Agrios Holdings recorded an increase in its product and service revenues and a slight increase in rental / IP revenues in the second quarter of fiscal 2019/2020, which ends March 31, 2020, representing a total increase of 8.54% over the previous quarter to USD 1.093 million compared to USD 1.007 million in the previous quarter.

    Revenues must increase significantly in Q3 and Q4 of the current 2019/2020 financial year in order to meet GBC Research's overall year guidance.

    Still on track

    For the current financial year 2019/2020e, analysts at GBC had previously forecast a small negative after-tax result of USD 1.5 million. They had expected the company to report negative cash flows in the first two quarters of the current 2019/2020 financial year. Only from the third quarter onwards should the operating cash flow turn positive. The company is well on the way to meeting these expectations.

    In the second quarter of 2019, EBITDA was USD -0.524 million, a significant improvement on the previous year's USD -1.789 million. EBIT also showed significant improvements and amounted to USD -0.615 million, which is significantly above the previous year's level of USD -1.843 million. The experts at GBC have raised their price target from CAD 1.38 to CAD 1.64 and confirmed the BUY rating.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Stefan Feulner on September 22nd, 2022 | 11:32 CEST

    BioNTech, XPhyto, Valneva - It is over!

    • Biotechnology
    • Covid19
    • Cannabis

    In an interview with the television station "CBS", the most powerful man in the world, US President Joe Biden, declared the pandemic over. While people in Germany have to wear face masks to the Oktoberfest in local and long-distance transport and then blare the latest hits from Mallorca in the marquee, without masks, of course, outside the former growth engine of Europe, relaxation seems to be setting in regarding COVID-19. A blow to the global vaccine industry! Meanwhile, a new market is growing unnoticed in the healthcare industry that could trigger a lasting trend in the near future.

    Read

    Commented by Nico Popp on September 1st, 2022 | 14:05 CEST

    New trending stock in the wings? Plug Power, Cardiol Therapeutics, BioNTech

    • Biotechnology
    • Cannabis
    • Hydrogen

    The markets want to go up! Last Friday, the Fed shock worried the markets, but today, even speculative stocks are picking up again. Especially stocks that were long considered deregistered can quickly develop potential. One example is Plug Power. Here, new demand in the wake of high energy prices meets good products. We explain the secret to the success of comeback stocks, using Plug Power as an example, and highlight new opportunities.

    Read

    Commented by Carsten Mainitz on February 4th, 2022 | 12:22 CET

    Novavax, Cardiol, MorphoSys - Here's the second wave of Corona vaccine plays!

    • Cannabis

    The number of new Corona infections reported to the Robert Koch Institute (RKI) within one day has reached an all-time high. 236,120 additional cases were recorded, bringing the number of people in Germany who were confirmed to be infected with Sars-CoV-2 to 10.4 million. However, the number of unreported cases is significantly higher. Vaccine manufacturers from the early days have been able to clear the table in recent months, and now new companies such as Novavax and Valneva are entering the scene. But not all innovative approaches to fighting Corona are on the radar of investors. These are perfect conditions for a second share price wave.

    Read